Active Supportive Care and Symptom Management Grants

PI Namesort ascending Organization - Company Title FOA
Hui, David University Of Tx Md Anderson Can Ctr Strategies for Persistent Agitated Delirium in Palliative Care PAR-18-559: Cancer Prevention and Control Clinical Trials Grant Program
Hui, David University Of Tx Md Anderson Can Ctr Efficacy and Safety of Rapid-Onset Opioids for Exertional Dyspnea in Cancer Patients PAR-18-559: Cancer Prevention and Control Clinical Trials Grant Program
Huberty, Jennifer Lynne University Of Texas Hlth Science Center Consumer-based meditation app, Calm, for treatment of sleep disturbance in hematological cancer patients PA-21-268: Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
Hu, Shuiying Ohio State University Prevention of paclitaxel-induced peripheral neuropathy with nilotinib RFA-CA-18-019: Research Answers to National Cancer Institute's (NCI) Provocative Questions
Hu, Jim Weill Medical Coll Of Cornell Univ Pelvic fascia spARing radical prostatectomy TrIAL (PARTIAL) PAR-21-035: Cancer Prevention and Control Clinical Trials Grant Program
Hoffman, Amy Jude University Of Nebraska Medical Center Managing Fatigue Using Virtual Reality for Post-Operative Lung Cancer Patients PA-16-160: NIH Research Project Grant
Hinds, Pamela S Children'S Research Institute Longitudinal, multimodal assessment of neuropsychological functioning in children diagnosed with high-risk acute lymphoblastic leukemia (HR-ALL): Using early changes to predict later impairment PA-16-160: NIH Research Project Grant
Hill, Deirdre University Of New Mexico Health Scis Ctr Chronic Kidney Disease Development in Cancer Treatment and Survival PAR-20-292: NCI Clinical and Translational Exploratory/Developmental Studies
Herrmann, Joerg Mayo Clinic Rochester TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) Trial PA-18-003: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity
Hanks, Brent Allen Duke University Role of the tumor NLRP3 inflammasome in the generation of anti-PD-1 antibody immunotherapy-associated toxicities PAR-19-325: Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies
Grueber, Wesley B Columbia University Health Sciences Neuron-macrophage interactions in models of chemotherapy-induced peripheral neuropathy PAR-20-292: NCI Clinical and Translational Exploratory/Developmental Studies
Gray, Robert J Dana-Farber Cancer Inst Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV) RFA-CA-17-052: Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability
Grace, Peter University Of Tx Md Anderson Can Ctr PQ12 Targeting HDAC6 for Chemotherapy-Induced Neuropathy and Chemobrain RFA-CA-17-017: Research Answers to NCI's Provocative Questions
Goode, Diana J University Of New England Novel expression of MHC class II on DRG neurons and its role in promoting antinociceptive CD4+ T cells in females during chemotherapy-induced peripheral neuropathy PA-20-185: NIH Research Project Grant
Gewandter, Jennifer University Of Rochester Wireless transcutaneous electrical stimulation (TENS) for chemotherapy-induced peripheral neuropathy: A phase II randomized clinical trial PA-18-159: Mechanisms, Models, Measurement, and Management in Pain Research

Pages